Welcome to our dedicated page for Voyager Acqsn SEC filings (Ticker: VACHU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Acquisition Corp (VACHU) is a Nasdaq-listed special purpose acquisition company (SPAC) and blank check company incorporated as an exempted company under the laws of the Cayman Islands. As a SPAC, its key regulatory disclosures are filed with the U.S. Securities and Exchange Commission (SEC) and relate to its initial public offering of units, its capital structure, and its efforts to complete a business combination.
In connection with its initial public offering of units consisting of Class A ordinary shares and redeemable warrants, Voyager filed a registration statement on Form S-1 that was declared effective by the SEC. That filing describes the unit structure, the terms of the warrants, the trust account arrangements, and the company’s plan to seek a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
Voyager has also announced that additional SEC filings will be made in connection with its definitive business combination agreement with VERAXA Biotech AG. These are expected to include a Current Report on Form 8-K containing an investor presentation about the proposed transaction, as well as a registration statement on Form F-4 that will include a proxy statement/prospectus of Voyager. Those documents are intended to provide details on the terms of the business combination, the proposed equity structure of the combined company, and the rights of Voyager’s public shareholders, including redemption rights.
On Stock Titan’s SEC filings page for VACHU, users can access Voyager Acquisition Corp’s historical and ongoing SEC submissions as they become available from EDGAR. The platform surfaces key forms such as registration statements and transaction-related filings, and applies AI-powered summaries to help explain complex documents, highlight important terms of the SPAC structure, and clarify how the proposed combination with VERAXA Biotech AG is structured from a regulatory and shareholder perspective.
Voyager Acquisition Corp. filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The sole purpose of this amendment is to add Exhibit 97.1, the company’s Policy on Recoupment of Incentive Compensation, which was adopted as of March 10, 2025 and was inadvertently omitted previously.
The company states that no other changes have been made, and the original annual report continues to speak as of, and for, the periods it covers. As context, the aggregate market value of outstanding Class A ordinary shares held by non‑affiliates was $263 million as of June 30, 2025, and there were 25,300,000 Class A ordinary shares and 6,325,000 Class B ordinary shares outstanding as of March 10, 2026.
Voyager Acquisition Corp. shareholders approved its business combination with VERAXA Biotech AG and related merger and charter proposals at a March 12, 2026 meeting. Holders of 25,217,315 Class A shares, representing approximately 99.67% of the Class A shares outstanding, exercised redemption rights. Assuming these elections are not withdrawn, about $885,556 will remain in the trust account and 82,685 Class A shares will convert into shares of the combined company, Veraxa Biotech Holding AG, which is expected to trade on Nasdaq under the symbol VRXA once closing conditions and listing approvals are satisfied.
Voyager Acquisition Corp. filed an update stating that VERAXA Biotech AG shareholders approved the merger structure with Veraxa Biotech Holding AG and the issuance of new shares to Voyager in connection with their proposed business combination.
At an Extraordinary General Meeting on February 27, 2026, VERAXA shareholders approved an absorption merger under which Veraxa Biotech Holding AG will acquire VERAXA and then be renamed Veraxa Biotech AG, with VERAXA continuing under its existing management. The meeting also approved an ordinary capital increase of up to CHF 223,400.00, with the corresponding number of shares to be offered to Voyager shareholders as part of the transaction. Completion of the business combination and listing of the combined company on Nasdaq under the symbol “VRXA” remain subject to Voyager shareholder approval and other closing conditions.
Voyager Acquisition Corp. received an updated large-holder report showing that investment firms managed by LMR collectively beneficially own 1,042,000 Class A Ordinary Shares. As of December 31, 2025, this stake represents about 4.1% of the company’s outstanding Class A shares.
The shares are held through LMR Multi-Strategy Master Fund Limited and LMR CCSA Master Fund Ltd, each directly owning 521,000 Class A shares. Each fund also holds warrants to purchase 544,500 additional Class A shares at an exercise price of $11.50, exercisable after Voyager completes its initial business combination.
LMR reports shared voting and dispositive power over all 1,042,000 shares, with no sole voting or dispositive power. The percentage ownership is based on 25,300,000 Class A shares outstanding as of November 14, 2025, as reported in Voyager’s Form 10-Q.
W. R. Berkley Corporation, through its subsidiary Berkley Insurance Company, reports beneficial ownership of 1,800,824 Class A ordinary shares of Voyager Acquisition Corp., equal to 7.1% of the class as of 12/31/2025.
The reporting persons have shared voting and dispositive power over all 1,800,824 shares and no sole voting or dispositive power. They state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Voyager Acquisition Corp.
Voyager Acquisition Corp. updated the terms of its planned merger with Veraxa Biotech AG. The parties signed a Second Amendment to their Business Combination Agreement, increasing the aggregate merger consideration to $1,350,000,000 from $1,300,000,000.
Veraxa agreed to waive a condition in the existing agreement so Voyager can ask its shareholders to amend its charter to remove a net tangible asset requirement of $5,000,001. This change is aimed at giving the company flexibility to complete the deal even with higher shareholder redemptions.
Separately, Voyager’s sponsor agreed in a First Amendment to the Sponsor Support Agreement that, at closing, it will forfeit for cancellation 200,000 Class B ordinary shares and 400,000 SPAC warrants for no consideration. An equivalent number of PubCo ordinary shares and PubCo warrants will instead be issued to Veraxa shareholders, modestly shifting economics toward the target’s owners.